Nursing Department, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiangya Nursing School, Central South University, Changsha, Hunan, China.
BMJ Open. 2023 Mar 20;13(3):e070294. doi: 10.1136/bmjopen-2022-070294.
Cancer diagnosis and treatment can impair fertility, and younger female patients with cancer have a particularly strong need for fertility preservation. Fertility preservation decision aids are thought to help patients make proactive and informed treatment decisions. This systematic review aims to assess the effectiveness and feasibility of online fertility preservation decision aids for young female patients with cancer.
PubMed, Web of Science Core Collection, Embase, The Cochrane Central Register of Controlled Trials, PsycINFO and CHINAL, along with three grey literature sources (Google Scholar, ClinicalTrials.gov and WHO International Clinical Trials Registry Platform), will be searched from each database's establishment to 30 November 2022. Two trained reviewers will independently screen the articles, and the data extraction and methodological quality of eligible randomised controlled trials and quasiexperimental studies will be assessed. A meta-analysis will be performed using Review Manager V.5.4 (Cochrane Collaboration) software, and heterogeneity will be assessed using I² statistics. If a meta-analysis is not possible, a narrative synthesis will be done.
Since this systematic review is based on published data, no ethical approval is required. The study's findings will be disseminated through peer-reviewed publications and conference presentations.
CRD42022363287.
癌症的诊断和治疗可能会损害生育能力,因此年轻的女性癌症患者对生育力保存有特别强烈的需求。生育力保存决策辅助工具被认为有助于患者做出积极主动且知情的治疗决策。本系统评价旨在评估针对年轻女性癌症患者的在线生育力保存决策辅助工具的有效性和可行性。
从每个数据库建立到 2022 年 11 月 30 日,将在 PubMed、Web of Science 核心合集、Embase、Cochrane 中央对照试验注册库、PsycINFO 和 CHINAL 以及三个灰色文献来源(Google Scholar、ClinicalTrials.gov 和 WHO 国际临床试验注册平台)上进行检索。两名经过培训的评审员将独立筛选文章,并评估合格的随机对照试验和准实验研究的数据提取和方法学质量。将使用 Cochrane 协作 Review Manager V.5.4 软件进行荟萃分析,并使用 I²统计量评估异质性。如果无法进行荟萃分析,则将进行叙述性综合。
由于本系统评价基于已发表的数据,因此不需要伦理批准。研究结果将通过同行评审的出版物和会议报告进行传播。
PROSPERO 注册号:CRD42022363287。